Dose-dependent pharmacokinetics of toxic metabolites is not related to increased toxicity following high-dose valproic acid in rats

Journal of Applied Toxicology

Volumn 30, Issue 8, 2010, Pages 775-778

  Jung, Byung Hwa ^a   Kim, Bo Jun ^b   Lee, Min Sun ^a   Lee, Joo Hyun ^b   Oh, Ju Hee ^b   Lee, Young Joo ^b  

^a Korea Institute of Science and Technology   (South Korea)

^b Kyung Hee University   (South Korea)

Author keywords

2,4 diene valproic acid; 4 ene valproic acid; Dose dependency; Pharmacokinetics; Toxicity; Valproic acid

Indexed keywords

2,4 DIENE VALPROIC ACID; 4 ENE VALPROIC ACID; DRUG METABOLITE; UNCLASSIFIED DRUG; VALPROIC ACID;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG HALF LIFE; DRUG MEGADOSE; DRUG METABOLISM; GAS CHROMATOGRAPHY; LIVER TOXICITY; MALE; MASS SPECTROMETRY; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; RAT; TIME TO MAXIMUM PLASMA CONCENTRATION; URINARY EXCRETION;

ADMINISTRATION, ORAL; ANIMALS; DOSE-RESPONSE RELATIONSHIP, DRUG; FATTY ACIDS, MONOUNSATURATED; GAS CHROMATOGRAPHY-MASS SPECTROMETRY; HUMANS; LIVER; MALE; NONLINEAR DYNAMICS; RATS; RATS, SPRAGUE-DAWLEY; VALPROIC ACID;

RATTUS;

EID: 78649683087     PISSN: 0260437X     EISSN: 10991263     Source Type: Journal    
DOI: 10.1002/jat.1608     Document Type: Article

References (20)

1. Anderson GD, Acheampong AA, Wilensky AJ, Levy RH. 1992. Effect of valproate dose on formation of hepatotoxic metabolites. Epilepsia 33(4): 736-742.
2. Brouwer KL, Hall ES, Pollack GM. 1993. Protein binding and hepatobiliary distribution of valproic acid and valproate glucuronide in rats. Biochem. Pharmacol. 45(3): 735-742.
3. Chiou WL. 1978. Critical evaluation of the potential error in pharmacokinetic studies of using the linear trapezoidal rule method for the calculation of the area under the plasma level-time curve. J. Pharmacokinet. Biopharm. 6(6): 539-546.
4. Cotariu D, Evans S, Zaidman JL, Marcus O. 1990. Early changes in hepatic redox homeostasis following treatment with a single dose of valproic acid. Biochem. Pharmacol, 40(3): 589-593.
5. Dickinson RG, Harland RC, Ilias AM, Rodgers RM, Kaufman SN, Lynn RK, Gerber N. 1979. Disposition of valproic acid in the rat: dose-dependent metabolism, distribution, enterohepatic recirculation and choleretic effect. J. Pharmacol. Exp. Ther. 211(3): 583-595.
6. Granneman GR, Wang SI, Machinist JM, Kesterson JW. 1984. Aspects of the metabolism of valproic acid. Xenobiotica 14(5): 375-387.
7. Lee MS, Lee YJ, Kim BJ, Shin KJ, Chung BC, Baek DJ, Jung BH. 2009. The relationship between glucuronide conjugate levels and hepatotoxicity after oral administration of valproic acid. Arch. Pharm. Res. 32(7): 1029-1035.
8. Loscher W. 1999. Valproate: a reappraisal of its pharmacodynamic properties and mechanisms of action. Prog. Neurobiol. 58(1): 31-59.
9. Murakami K, Sugimoto T, Nishida N, Kobayashi Y, Kuhara T, Matsumoto I. 1992. Abnormal metabolism of carnitine and valproate in a case of acute encephalopathy during chronic valproate therapy. Brain Dev. 14(3): 178-181.
10. Oh JH, Park SE, Shim CK, Lee YJ. 2009. Biliary clearance of bromosulfophthalein in anesthetized and freely moving conscious rat. Biopharm. Drug Dispos. 30(2): 94-98.
11. Pollack GM, Brouwer KL. 1991. Physiologic and metabolic influences on enterohepatic recirculation: simulations based upon the disposition of valproic acid in the rat. J. Pharmacokinet. Biopharm. 19(2): 189-225.
12. Rettenmeier AW, Prickett KS, Gordon WP, Bjorge SM, Chang SL, Levy RH, Baillie TA. 1985. Studies on the biotransformation in the perfused rat liver of 2-n-propyl-4-pentenoic acid, a metabolite of the antiepileptic drug valproic acid. Evidence for the formation of chemically reactive intermediates. Drug Metab. Dispos. 13(1): 81-96.
13. Rettenmeier AW, Gordon WP, Prickett KS, Levy RH, Baillie TA. 1986. Biotransformation and pharmacokinetics in the rhesus monkey of 2-n-propyl-4-pentenoic acid, a toxic metabolite of valproic acid. Drug. Metab. Dispos. 14(4): 454-464.
14. Seçkin Ş, Başaran-Küçükgergin C, Uysal M. 1999. Effect of acute and chronic administration of sodium valproate on lipid peroxidation and antioxidant system in rat liver. Pharmacol. Toxicol. 85: 294-298.
15. Sugimoto T, Nishida N, Yasuhara A, Ono A, Sakane Y, Matsumura T. 1983. Reye-like syndrome associated with valproic acid. Brain Dev. 5(3): 334-337.
16. Tang W, Abbott FS. 1997. A comparative investigation of 2-propyl-4-pentenoic acid (4-ene VPA) and its alpha-fluorinated analogue: phase II metabolism and pharmacokinetics. Drug Metab. Dispos. 25(2): 219-227.
17. Tang W, Borel AG, Abbott FS. 1996. Conjugation of glutathione with a toxic metabolite of valproic acid, (E)-2-propyl-2, 4-pentadienoic acid, catalyzed by rat hepatic glutathione-S-transferases. Drug Metab. Dispos. 24(4): 436-446.
18. Ubeda N, Alonso-Aperte E, Varela-Moreiras G. 2002. Acute valproate administration impairs methionine metabolism in rats. J. Nutr. 132: 2737-2742.
19. Yu HY, Wu MS, Shen YZ. 1993. Nonlinear elimination and hepatic concentration of conjugation-metabolite of valproate in guinea-pigs. Biopharm. Drug Dispos. 14(4): 297-312.
20. Zimmerman HJ, Ishak KG. 1982. Valproate-induced hepatic injury: analyses of 23 fatal cases. Hepatology 2(5): 591-597.